Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study(†)

We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCβ] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Butowski, Nicholas, Chang, Susan M., Lamborn, Kathleen R., Polley, Mei Yin, Parvataneni, R., Hristova-Kazmierski, Maria, Musib, Luna, Nicol, Steven J., Thornton, Donald E., Prados, Michael D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940647/
https://ncbi.nlm.nih.gov/pubmed/20156802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop070
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados